Boston Scientific Announced FDA Approval of ImageReady MRI For Vercise Gevia Deep Brain Stimulation System

Boston Scientific Corporation is a manufacturer, and also engaged in the commercialization of medical devices which are used in wide range of medical specialties. The company offers products for the major seven core businesses such as interventional cardiology, cardiac rhythm management, endoscopy, peripheral interventions, urology and pelvic health, neuromodulation and electrophysiology. The company is operating through three segments namely, MedSurg, Rhythm & Neuro and Cardiovascular. The MedSurg comprises endoscopy and urology and pelvic health segments. The endoscopy business develops and manufactures devices to diagnose and treat a wide range of gastrointestinal (GI) and pulmonary conditions with innovative, less invasive technologies. On the other hand, the urology and pelvic health segment involved in developing and manufacturing devices to treat various urological and pelvic conditions kidney stones, prostate cancer, benign prostatic hyperplasia (BPH), erectile dysfunction, pelvic floor disorders, male incontinence, abnormal uterine bleeding and uterine fibroids & polyps. The Rhythm & Neuro segment covers cardiac rhythm management, electrophysiology and neuromodulation areas. Whereas, the cardiovascular segment involves interventional cardiology and peripheral interventions.

Boston Scientific Corporation received FDA approval for its ImageReady MRI labeling for the Vercise Gevia Deep Brain Stimulation (DBS) System to be used in a full-body magnetic resonance imaging (MRI) environment. Strong international operations with six principal international manufacturing facilities, across Ireland, Costa Rica and Puerto Rico. Product marketing done in 100 countries through its direct sales force, which is actively supporting in 40 countries. The business segments of Boston are focusing towards implementation of new measures to improve its existing position in the market.